HOUSTON, Nov. 26, 2013 /PRNewswire/ -- The Burzynski Clinic (BC) announced today that it has presented the results of a phase II study of antineoplastons A10 and AS2-1 (ANP) in adult patients with recurrent glioblastoma multiforme (GBM) at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology in San Francisco. GBM accounts for 60% of the primary brain tumors in adults and represents the most frequently occurring and the most malignant form of such tumors. Treatment for recurrent GBM creates one of the most difficult challenges in neuro-oncology. The study, presented at the poster session, accrued patients who developed disease progression during standard treatment within 8 weeks of completion of radiation therapy and 6 weeks from the completion of chemotherapy. 24 cases of recurrent GBM that progressed during prior standard treatment were eligible for evaluation. ANP was administered intravenously for a median duration of 13 weeks. Responses were assessed by magnetic resonance imaging (MRI). Complete and partial responses were determined in 17% of cases. Overall survival is 39% at 1 year and 4.4% at 2 years, 5 and 10 years. The treatment was well-tolerated with reversible grades 3 and 4 toxicities including four cases of hypernatremia, two of fatigue, two of hyperkalemia, and a single case of somnolence. There were no chronic toxicities.
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic's ability to use personalized targeted cancer therapy. Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.
SOURCE Burzynski Clinic